CatalystMarker
← board

CHUC

distress 3/10 · well-funded / low risk
$0.17-3%today-54% from 52w high
charliesholdings.com35 employeesFounded 2014Costa Mesa, CATobacco
Revenue
pre-revenue
Liquidity
$0M
Runway
—
Shares 1y
+7%

Price & events

-47.1% over 6M
$0.16$0.24$0.32Jan 26Apr 26Jul 261.2Mfinancing: 8-K private_placement (2026-05-21)financing: 8-K private_placement (2026-02-13)
CatalystRating changeDilutionFinancingdashed = today
-2.9%
1D
-22.7%
1W
-29.2%
1M
-29.2%
3M
-47.1%
6M
+87.0%
1Y
-3.7%
2Y
-44.3%
5Y
-45.2%
All

Overview

Market Cap
$47.69M
Enterprise Value
$50.83M
Volume
65.40K
52 Week Range
$0.09 – $0.37
Total Shares
280.55M
Float Shares
110.85M
% Held by Insiders
57.00%
% Held by Institutions
4.31%
RVOL
1.22x
Beta
1.30

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 280,553,242 · 0 offerings/1y · 2 PIPEs
  • 2026-05-218-Kprivate_placement
  • 2026-02-138-Kprivate_placement
  • 2025-08-118-Kmaterial_agreement
  • 2025-06-038-Kmaterial_agreement
  • 2025-04-178-Kmaterial_agreement
  • 2024-11-278-Kprivate_placement
  • 2024-11-12SC 13G/Astrategic_stake
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.